@obmdmom's GLP-1 pregnancy advice, fact-checked

What did @obmdmom actually say?

Dr. Emma, an OB-GYN and Maternal Fetal Medicine specialist, made several distinct claims in this video. She said GLP-1 receptor agonists are "like quite literally the opposite of birth control" because they appear to restore ovulation in women with irregular cycles, including those with PCOS and type 2 diabetes. She also said these medications should be stopped as soon as pregnancy is discovered, that there are no randomized clinical trials on GLP-1 use in pregnancy, and that women should ideally stop the medication two months before trying to conceive. She drew a direct parallel to the bariatric surgery population, where restored fertility caught patients off guard after years of assuming they were infertile.

Her core message: if you are on a GLP-1 and not trying to get pregnant, use contraception. If you are trying to conceive, stop it two months before.

Does the science back this up?

On the fertility restoration piece, yes, the evidence is building, though it is not rock solid. The claim that GLP-1 drugs improve menstrual regularity in women with PCOS is supported by several observational studies, including work by Jensterle et al. (2019, Journal of Clinical Endocrinology and Metabolism) showing liraglutide improved menstrual frequency in PCOS patients independent of major weight loss. The "5 to 10% body weight" threshold she mentions is consistent with what the reproductive endocrinology literature has observed for resumption of ovulation.

On the pregnancy safety piece, her statement that there are no randomized clinical trials is accurate as of 2024. The available data comes from pregnancy registries and pharmacovigilance reports. A 2023 analysis using Danish registry data (Winther et al., 2023, Diabetes Care) found no significant increase in major congenital malformations in women exposed to GLP-1 agonists in early pregnancy compared to unexposed controls, which aligns with her claim that it "seems probably fine" if stopped early.

What did they get wrong (or right)?

She got the broad strokes right, but a few things deserve scrutiny.

• The "two months before conception" recommendation is reasonable for semaglutide given its roughly five-week half-life, and the prescribing information for Wegovy and Ozempic does recommend stopping two months prior to planned pregnancy. She presented this correctly, though she did not explain why, which would have been useful context.
• Cardio and kidney protective benefits are well-documented for semaglutide and liraglutide in high-risk populations (Marso et al., 2016, NEJM for LEADER trial; Perkovic et al., 2024, NEJM for semaglutide in CKD). Giving her credit here.
• The bariatric surgery parallel is scientifically sound and frequently cited in reproductive medicine. The recommendation to wait two years post-bariatric surgery before conception is standard, though adherence is notoriously poor, as she acknowledged.
• One overstep: she said "we think it's probably fine" regarding early GLP-1 exposure in pregnancy. That is a reasonable clinical opinion, but framing it as reassurance to a general audience of 53,000 viewers is a stretch. The Winther 2023 data is reassuring, but the sample sizes remain limited and longer-term developmental outcomes in exposed infants are not yet known.

What should you actually know?

A few things the video either skipped or undersold.

First, the fertility restoration effect is not guaranteed or universal. Women with PCOS or hypothalamic dysfunction related to obesity may see improvements, but GLP-1 drugs are not fertility treatments and have not been approved for that indication.

Second, the contraception interaction matters more than most people realize. There is evidence that oral contraceptives may have delayed absorption when taken alongside GLP-1 agonists due to slowed gastric emptying (Kusminski et al., 2023, Obesity Reviews). If you rely on oral pills for contraception and you are on a GLP-1, that is worth discussing with your prescriber.

Third, stopping a GLP-1 drug is not always simple. Weight regain can begin quickly after discontinuation, and for women managing type 2 diabetes, stopping without an alternative management plan carries its own risks. This decision should happen in coordination with both your prescribing physician and your OB-GYN, not unilaterally.